00000nam 22000008a 4500 9.865656 CaOODSP 20221107161841 cr ||||||||||| 181205t20192014onc #o f000 0 eng d 9780660288628 CaOODSP eng n-cn--- HP40-243/2018E-PDF Literature review on the immunogenicity of herpes zoster vaccines [electronic resource]. [Ottawa] : Public Health Agency of Canada, 2019. 46 p. Issued also in French under title: Revue de la littérature sur l'immunogénicité des vaccins contre le zona. "Publication date: January 2019." "An Advisory Committee Review (ACR), National Advisory Committee on Immunization (NACI)." Cover title. Includes bibliographical references. "Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines"--Executive summary, p. 3. gccst Immunization Public Health Agency of Canada. Revue de la littérature sur l'immunogénicité des vaccins contre le zona (CaOODSP)9.865657 PDF 1.56 MB https://publications.gc.ca/collections/collection_2019/aspc-phac/HP40-243-2018-eng.pdf Pub. : 180582